This achievement reinforces Shenandoah Oncology's commitment to advancing cancer care through innovative clinical research.
Winchester, Va. — Shenandoah Oncology is proud to announce its participation in a new international clinical trial evaluating a novel bispecific therapy for patients with metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). Through its collaboration with Sarah Cannon Research Institute (SCRI), Shenandoah Oncology was the first site in the world to enroll a participant in the Phase III study. This positions the practice at the forefront of next-generation cancer care.
The clinical trial is evaluating an investigational therapy designed to assess the safety and efficacy of a novel bispecific treatment approach for patients with metastatic EGFR-mutated NSCLC whose disease has progressed following prior treatment. Bispecific therapies are engineered to bind to two different targets simultaneously, helping the immune system more effectively identify and attack cancer cells.
"This study represents an exciting opportunity to evaluate a promising new treatment approach for patients with advanced EGFR-mutated lung cancer,” said Michael McCusker, MD, medical oncologist at Shenandoah Oncology. “Our participation reflects Shenandoah Oncology's commitment to bringing leading-edge research and innovative therapies to the patients we serve."
Non-small cell lung cancer is the most common form of lung cancer, accounting for approximately 85% of all lung cancer diagnoses. Among these patients, a subset carries mutations in the EGFR gene, which can drive cancer growth. Although targeted therapies have improved treatment outcomes for many patients with EGFR-mutated NSCLC, disease progression remains a significant challenge, highlighting the need for additional treatment options.
The trial's primary objective is to evaluate whether the investigational therapy can improve clinical outcomes compared with current standard treatment approaches, including measures such as progression-free survival, overall survival, safety and tolerability. The study will enroll participants at sites around the world to determine whether this new treatment strategy can provide meaningful benefits for patients with advanced disease.
Through its collaboration with SCRI, Shenandoah Oncology continues to expand access to innovative clinical trials and cutting-edge therapies for patients throughout the region. Leveraging SCRI's Accelero model, Shenandoah Oncology achieved rapid trial activation and successfully enrolled the first patient globally. Participation in such studies reflect the organization's longstanding commitment to advancing cancer research while providing patients with access to promising new treatment options without requiring travel to major academic medical centers.
"Our patients benefit from access to innovative treatment options close to home,” said Dr. McCusker. “We’re proud to provide that access while contributing to research that may help advance care for future patients facing this disease.”
As the first site in the world to enroll a participant in this study, Shenandoah Oncology further demonstrates its leadership in community-based cancer research and its dedication to helping accelerate the development of new treatment approaches for patients with lung cancer.
About Shenandoah Oncology
Shenandoah Oncology is a part of The US Oncology Network (The Network), an organization of approximately 3,300 independent providers committed to advancing high-quality, value-based cancer care. As part of The Network, Shenandoah Oncology engages in shared learning, clinical collaboration, and continuous innovation to elevate the standard of care. Supported by McKesson, The Network provides robust infrastructure and operational support, empowering providers to focus on delivering compassionate, personalized care — close to home.
Shenandoah Oncology also participates in clinical trials through Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted more than 900 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA in the past decade.
Media Contact